Literature DB >> 22138150

The expression of Visinin-like 1 during mouse embryonic development.

Roxana Ola1, Sylvie Lefebvre, Karl-Heinz Braunewell, Kirsi Sainio, Hannu Sariola.   

Abstract

Visinin like 1 (Vsnl1) encodes a calcium binding protein which is well conserved between species. It was originally found in the brain and its biological functions in central nervous system have been addressed in several studies. Low expression levels have also been found in some peripheral organs, but very little information is available regarding its physiological roles in non-neuronal tissues. Except for the kidney, the expression pattern of Vsnl1 mRNA and protein has not yet been addressed during embryogenesis. By in situ hybridization and immunolabeling we have extensively analyzed the expression pattern of Vsnl1 during murine development. Vsnl1 specifies the cardiac primordia and its expression becomes restricted to the atrial myocardium after heart looping. However, in the adult heart, Vsnl1 is expressed by all four cardiac chambers. It also serves as a specific marker for the cardiomyocyte-derived structures in the systemic and pulmonary circulation. Vsnl1 is dynamically expressed also by many other organs during development e.g. taste buds, cochlea, thyroid, tooth, salivary and adrenal gland. The stage specific expression pattern of Vsnl1 makes it a potentially useful marker particularly in studies of cardiac and vascular morphogenesis.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138150     DOI: 10.1016/j.gep.2011.11.004

Source DB:  PubMed          Journal:  Gene Expr Patterns        ISSN: 1567-133X            Impact factor:   1.224


  2 in total

1.  Pax3 and Tbx5 specify whether PDGFRα+ cells assume skeletal or cardiac muscle fate in differentiating embryonic stem cells.

Authors:  Alessandro Magli; Erin Schnettler; Scott A Swanson; Luciene Borges; Kirsta Hoffman; Ron Stewart; James A Thomson; Susan A Keirstead; Rita C R Perlingeiro
Journal:  Stem Cells       Date:  2014-08       Impact factor: 6.277

2.  Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial.

Authors:  Takashi Oshima; Akira Tsuburaya; Kazuhiro Yoshida; Takaki Yoshikawa; Yohei Miyagi; Yasushi Rino; Munetaka Masuda; Jia Guan; Patrick Tan; Heike I Grabsch; Junichi Sakamoto; Shiro Tanaka
Journal:  Sci Rep       Date:  2022-05-20       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.